BLCM Bellicum Pharmaceuticals Inc.

11.41
+0.12  (1%)
Previous Close 11.29
Open 11.29
Price To book 3.09
Market Cap 379114582
Shares 33,226,519
Volume 501,435
Short Ratio 5.44
Av. Daily Volume 770,104

SEC filingsSee all SEC filings

  1. S-8 - Securities to be offered to employees in employee benefit plans 171052040
  2. 8-K - Current report 171034101
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014853
  4. 8-K - Current report 171014794
  5. EFFECT - Notice of Effectiveness 17962590

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 planned 2H 2016
BPX-401
Hematological cancers that express the CD19 antigen
Phase 1/2 update June 23, 2017.
BPX-501 - BP-004
Adjunct T-cell therapy administered after allogeneic HSCT - (hematopoietic stem cell transplantation) - cancer
Phase 2 trial initiation of dosing announced February 21, 2017.
BPX-601
Pancreatic cancer
Phase 1/2 commenced March 2017.
BPX-701
PRAME (preferentially-expressed antigen in melanoma) -expressing melanoma, sarcomas and neuroblastoma cancer

Latest News

  1. Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : September 11, 2017
  2. Bellicum Pharmaceuticals, Inc. – Value Analysis (NASDAQ:BLCM) : September 6, 2017
  3. Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : September 1, 2017
  4. Bellicum Pharmaceuticals to Present at Three Healthcare Investor Conferences in September
  5. Bellicum Pharmaceuticals (BLCM) in Focus: Stock Moves 13.8% Higher
  6. Edited Transcript of BLCM earnings conference call or presentation 8-Aug-17 9:00pm GMT
  7. Houston pharma co. shakes up C-suite again
  8. Bellicum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
  9. Investor Network: Bellicum Pharmaceuticals Inc. to Host Earnings Call
  10. Bellicum Pharmaceuticals Appoints Gregory Naeve as Chief Business Officer
  11. Bellicum Pharmaceuticals to Report Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8, 2017
  12. Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : July 28, 2017
  13. ETFs with exposure to Bellicum Pharmaceuticals, Inc. : July 24, 2017
  14. 5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote
  15. 3 Value Stocks for Sharp Investors
  16. Can Bellicum Pharmaceuticals Stock Bounce Back?
  17. Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : July 14, 2017
  18. Bellicum Pharmaceuticals, Inc. – Value Analysis (NASDAQ:BLCM) : July 3, 2017
  19. Bellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : June 30, 2017